OS at 36 months

P-value

EFS at 36 months

P-value

Study patients (n = 73)

63.3%

51.3%

Age (years)

< 1.5

≥ 1.5 < 5

≥ 5

66.7%

58.7%

73.8%

0.31

66.6%

46.7%

66.2%

0.49

Stage

III

IV

68.1%

62.7%

0.54

52.6%

51.0%

0.626

MYCN status

Amplified

Not amplified

Unknown

51.1%

63.1%

100%

0.428

49.0%

52.6%

50.0%

0.96

Bone marrow infiltration

No

Yes

Unknown

70.7%

59.3%

100%

0.15

58.9%

46.8%

0%

0.15

Bone metastasis

No

Yes

Unknown

62.2%

63.5%

100%

0.402

56.1%

44.4%

100%

0.09%

Brain metastasis

No

Yes

69.4%

83.3%

0.425

48.7%

83.3%

0.211

Liver metastasis

No

Yes

64.5%

33.3%

0.236

51.9%

33.3%

0.499

Distant lymph node involvement

No

Yes

68.1%

61.6%

0.08

55.1%

50.1%

0.44

Post-induction CTh response

CR/VGPR/PR

Less than PR

64.2%

63.5%

0.75

53.3%

49.3

0.45

Extent of surgical resection

Complete resection

Less than complete resection

No surgical intervention

50.5%

56.3%

75.1%

0.4

42.7%

41.7

63.7%

0.44

Disease status at time of transplant

CR/VGPR/PR

60.7%

81.8%

0.34

50.1%

60.6%

0.54